利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.03 秒)

    Immunogenic compositions
    2.
    发明授权
    Immunogenic compositions 有权
    免疫原性组成

    公开(公告)号：US09327021B2

    公开(公告)日：2016-05-03

    申请号：US13885485

    申请日：2011-11-15

    申请人： Scott Gallichan ,  Ausra Mancevski ,  Nathalie Reveneau ,  Jin Su ,  Francois Dalencon ,  Jean Haensler

    发明人： Scott Gallichan ,  Ausra Mancevski ,  Nathalie Reveneau ,  Jin Su ,  Francois Dalencon ,  Jean Haensler

    IPC分类号： A61K6/00 ,  A61K39/39 ,  A61K38/00 ,  A61K39/02 ,  A61K9/00 ,  A61K9/107 ,  A61K39/118 ,  A61K47/44 ,  A61K39/00

    CPC分类号： A61K39/39 ,  A61K9/0019 ,  A61K9/107 ,  A61K9/1075 ,  A61K39/118 ,  A61K47/44 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/572 ,  A61K2039/575

    摘要： The present invention provides compositions comprising a Chlamydial major outer membrane protein (referenced herein as “MOMP”), from at least one Chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product E6020 having CAS Number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle). The MOMP protein may be derived from any species of Chlamydia (e.g., C. trachomatis, C. pneumoniae, C. psittaci, or C. trachomatis MoPn). In preferred embodiments, the composition comprises one or more major outer membrane proteins each derived from different serovars of C. trachomatis. The invention also provides methods of inducing an immune response to a Chlamydia species (e.g., C. trachomatis) in a subject, by administering to the subject a composition of the invention.

    摘要翻译： 本发明提供了包含来自至少一种衣原体血清型和佐剂的衣原体主要外膜蛋白（本文称为“MOMP”）的组合物，其特征在于所述佐剂包含具有CAS号287180-63-6的产物E6020。 该组合物还可以包含至少一种载体体系（例如乳液，矿物颗粒）。 MOMP蛋白可以衍生自衣原体（例如沙眼衣原体，沙眼衣原体，肺炎衣原体，鹦鹉热鹦鹉或C.沙眼衣原体MoPn）的任何种类。 在优选的实施方案中，组合物包含一种或多种主要的外膜蛋白，其各自衍生自沙眼衣原体的不同血清型。 本发明还提供了通过向受试者施用本发明的组合物来诱导受试者对衣原体（例如沙眼衣原体）的免疫应答的方法。

    Immunogenic Compositions
    3.
    发明申请
    Immunogenic Compositions 有权
    免疫原性组合物

    公开(公告)号：US20130344109A1

    公开(公告)日：2013-12-26

    申请号：US13885485

    申请日：2011-11-15

    申请人： Scott Gallichan ,  Ausra Mancevski ,  Nathalie Reveneau ,  Jin Su ,  Francois Dalencon ,  Jean Haensler

    发明人： Scott Gallichan ,  Ausra Mancevski ,  Nathalie Reveneau ,  Jin Su ,  Francois Dalencon ,  Jean Haensler

    IPC分类号： A61K39/39

    CPC分类号： A61K39/39 ,  A61K9/0019 ,  A61K9/107 ,  A61K9/1075 ,  A61K39/118 ,  A61K47/44 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/572 ,  A61K2039/575

    摘要： The present invention provides compositions comprising a Chlamydial major outer membrane protein (referenced herein as “MOMP”), from at least one Chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product E6020 having CAS Number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle). The MOMP protein may be derived from any species of Chlamydia (e.g., C. trachomatis, C. pneumoniae, C. psittaci, or C. trachomatis MoPn). In preferred embodiments, the composition comprises one or more major outer membrane proteins each derived from different serovars of C. trachomatis. The invention also provides methods of inducing an immune response to a Chlamydia species (e.g., C. trachomatis) in a subject, by administering to the subject a composition of the invention.

    摘要翻译： 本发明提供了包含来自至少一种衣原体血清型和佐剂的衣原体主要外膜蛋白（本文称为“MOMP”）的组合物，其特征在于所述佐剂包含具有CAS号287180-63-6的产物E6020。 该组合物还可以包含至少一种载体体系（例如乳液，矿物颗粒）。 MOMP蛋白可以衍生自衣原体（例如沙眼衣原体，沙眼衣原体，肺炎衣原体，鹦鹉热鹦鹉或C.沙眼衣原体MoPn）的任何种类。 在优选的实施方案中，组合物包含一种或多种主要的外膜蛋白，其各自衍生自沙眼衣原体的不同血清型。 本发明还提供了通过向受试者施用本发明的组合物来诱导受试者对衣原体（例如沙眼衣原体）的免疫应答的方法。

    Meningococcal Vaccine Based on Lipooligosaccharide (LOS) and Neisseria Meningitidis Protein
    4.
    发明申请
    Meningococcal Vaccine Based on Lipooligosaccharide (LOS) and Neisseria Meningitidis Protein 审中-公开
    基于脂多糖（LOS）和脑膜炎奈瑟氏球菌蛋白的脑膜炎球菌疫苗

    公开(公告)号：US20120156281A1

    公开(公告)日：2012-06-21

    申请号：US13319868

    申请日：2010-05-12

    申请人： Jean Haensler ,  Bruno Guy ,  Noëlle Mistretta ,  Monique Moreau ,  Geneviève Renauld-Mongenie ,  Bachra Rokbi

    发明人： Jean Haensler ,  Bruno Guy ,  Noëlle Mistretta ,  Monique Moreau ,  Geneviève Renauld-Mongenie ,  Bachra Rokbi

    IPC分类号： A61K39/095 ,  A61P37/04 ,  A61P31/04 ,  A61K9/127

    CPC分类号： A61K39/095

    摘要： The invention relates to a vaccine against N. meningitidis infections, comprising (i) an N. meningitidis LOS especially consisting of a lipid A, an inner core, and an L8-type α chain in which the heptose II residue of the inner core (a) carries a phosphoethanolamine (PEA) substituent in position O-3, and does not carry a PEA substituent in positions O-6 and O-7, or (b) carries a phosphoethanolamine (PEA) substituent in position O-3 and in position O-6 or O-7; and (ii) the lipidated sub-unit B (TbpB) of the receptor of the human transferrine of an N. meningitidis strain or a lipid fragment of said TbpB.

    摘要翻译： 本发明涉及一种针对脑膜炎奈瑟氏球菌感染的疫苗，其包含（i）脑膜炎奈瑟氏球菌LOS，特别由脂质A，内核和L8型α链组成，其中内核的肝脏II残基 a）在位置O-3处携带磷酸乙醇胺（PEA）取代基，并且在O-6和O-7位置不携带PEA取代基，或（b）在O-3位置携带磷酸乙醇胺（PEA）取代基， 位置O-6或O-7; 和（ii）脑膜炎奈瑟氏球菌菌株的人运动素受体的脂质化亚单元B（TbpB）或所述TbpB的脂质片段。

    Detoxification method for lipopolysaccharide (LPS) or lipid A of gram-negative bacteria
    5.
    发明申请
    Detoxification method for lipopolysaccharide (LPS) or lipid A of gram-negative bacteria 审中-公开
    革兰氏阴性细菌的脂多糖（LPS）或脂质A的解毒方法

    公开(公告)号：US20100291192A1

    公开(公告)日：2010-11-18

    申请号：US12800426

    申请日：2010-05-14

    申请人： Jean Haensler ,  François Dalençon ,  Monique Moreau ,  Noëlle Mistretta

    发明人： Jean Haensler ,  François Dalençon ,  Monique Moreau ,  Noëlle Mistretta

    IPC分类号： A61K39/02 ,  A61K35/74 ,  A61K9/127 ,  A61P31/04

    CPC分类号： A61K39/095 ,  A61K9/127 ,  A61K9/1272 ,  A61K39/02 ,  A61K39/39 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/55583

    摘要： The invention relates to a method of detoxifying a lipopolysaccharide (LPS) or a lipid A from a Gram-negative bacterium, which comprises mixing the LPS or the lipid A with a cationic lipid so as to form a complex in which the LPS or the lipid A is associated with the cationic lipid. According to the conventional preparation modes, the cationic lipid with the co-lipid, if this latter is present, get(s) structured into complexes i.a. liposomes. When preparing lipidic complexes, the addition of LPS or Lipid A leads to an association of this latter with the cationic lipid and as a result, the LPS or lipid A is substantially detoxified. The LPS or lipid A detoxified by the complexes, e.g. when incorporated into liposomes, can be used as vaccinal antigen or as adjuvant.

    摘要翻译： 本发明涉及从革兰氏阴性细菌中解毒脂多糖（LPS）或脂质A的方法，其包括将LPS或脂质A与阳离子脂质混合以形成其中LPS或脂质 A与阳离子脂质有关。 根据常规的制备方式，具有共同脂质的阳离子脂质如果存在，则将其结构化成复合物。 脂质体。 当制备脂质复合物时，加入LPS或脂质A导致后者与阳离子脂质的结合，结果是LPS或脂质A基本上解毒。 由复合物解毒的LPS或脂质A，例如 当掺入脂质体时，可用作疫苗抗原或佐剂。

    Method for adjuvanting lipopolysaccharide (LPS) of gram-negative bacteria
    6.
    发明授权
    Method for adjuvanting lipopolysaccharide (LPS) of gram-negative bacteria 有权
    用于佐剂革兰氏阴性菌的脂多糖（LPS）的方法

    公开(公告)号：US08506971B2

    公开(公告)日：2013-08-13

    申请号：US12780388

    申请日：2010-05-14

    申请人： Jean Haensler ,  Bruno Guy

    发明人： Jean Haensler ,  Bruno Guy

    IPC分类号： A61K45/00 ,  A61K39/385 ,  A61K39/02 ,  A61K39/095 ,  A01N25/26

    CPC分类号： A61K39/095 ,  A61K9/1272 ,  A61K9/1277 ,  A61K39/02 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/6068

    摘要： The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) of Neisseria meningitidis or a lipidated fragment thereof; or (ii) LPS and the lipidated TbpB of N. meningitidis or a lipidated fragment thereof are formulated together in liposomes; or (iii) LPS is conjugated with the lipidated TbpB of N. meningitidis or a lipidated fragment thereof; in order to obtain a preparation which does not contain OMVs and which is capable of inducing, after administration to a mammal, an anti-LPS immune response which is improved by comparison with the anti-LPS immune response observed after administration of the corresponding preparation in which the lipidated TbpB of N. meningitidis or a lipidated fragment thereof is omitted; as well as vaccine compositions thereof. The LPS may, for example, be the LOS of a non-enteric Gram-negative bacterium such as N. meningitidis.

    摘要翻译： 本发明的主题是用于对革兰氏阴性细菌的LPS进行佐剂化的方法，根据该方法将LPS或LPS脂质体（脂质体中配制的LPS）与脂质化的人 - 转铁蛋白受体亚基B（TbpB蛋白）混合 脑膜炎奈瑟氏球菌或其脂化片段; 或（ii）LPS和脑膜炎奈瑟氏球菌的脂化TbpB或其脂化片段一起配制在脂质体中; 或（iii）LPS与脑膜炎奈瑟氏球菌的脂化TbpB或其脂化片段缀合; 为了获得不含OMV的制剂，并且能够在给予哺乳动物之后诱导抗LPS免疫应答，所述抗LPS免疫应答与通过将相应制剂给药后观察到的抗LPS免疫应答相比得到改善 脑膜炎奈瑟氏球菌的脂质化TbpB或其脂化片段被省略; 以及其疫苗组合物。 LPS可以是例如非肠溶革兰氏阴性细菌如脑膜炎奈瑟氏球菌的LOS。

    Method for adjuvanting lipopolysaccharide (LPS) of Gram-negative bacteria
    7.
    发明申请
    Method for adjuvanting lipopolysaccharide (LPS) of Gram-negative bacteria 有权
    革兰阴性菌的脂多糖（LPS）佐剂的方法

    公开(公告)号：US20110014272A1

    公开(公告)日：2011-01-20

    申请号：US12780388

    申请日：2010-05-14

    申请人： Jean Haensler ,  Bruno Guy

    发明人： Jean Haensler ,  Bruno Guy

    IPC分类号： A61K9/127 ,  C07K17/02 ,  A61K39/385 ,  A61K39/095 ,  A61P31/04

    CPC分类号： A61K39/095 ,  A61K9/1272 ,  A61K9/1277 ,  A61K39/02 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/6068

    摘要： The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) of Neisseria meningitidis or a lipidated fragment thereof; or (ii) LPS and the lipidated TbpB of N. meningitidis or a lipidated fragment thereof are formulated together in liposomes; or (iii) LPS is conjugated with the lipidated TbpB of N. meningitidis or a lipidated fragment thereof; in order to obtain a preparation which does not contain OMVs and which is capable of inducing, after administration to a mammal, an anti-LPS immune response which is improved by comparison with the anti-LPS immune response observed after administration of the corresponding preparation in which the lipidated TbpB of N. meningitidis or a lipidated fragment thereof is omitted; as well as vaccine compositions thereof. The LPS may, for example, be the LOS of a non-enteric Gram-negative bacterium such as N. meningitidis.

    摘要翻译： 本发明的主题是用于对革兰氏阴性细菌的LPS进行佐剂化的方法，根据该方法将LPS或LPS脂质体（脂质体中配制的LPS）与脂质化的人 - 转铁蛋白受体亚基B（TbpB蛋白）混合 脑膜炎奈瑟氏球菌或其脂化片段; 或（ii）LPS和脑膜炎奈瑟氏球菌的脂化TbpB或其脂化片段一起配制在脂质体中; 或（iii）LPS与脑膜炎奈瑟氏球菌的脂化TbpB或其脂化片段缀合; 为了获得不含OMV的制剂，并且能够在给予哺乳动物之后诱导抗LPS免疫应答，所述抗LPS免疫应答与通过将相应制剂给药后观察到的抗LPS免疫应答相比得到改善 脑膜炎奈瑟氏球菌的脂质化TbpB或其脂化片段被省略; 以及其疫苗组合物。 LPS可以是例如非肠溶革兰氏阴性细菌如脑膜炎奈瑟氏球菌的LOS。

    Pharmaceutical composition for immunization against AIDS
    8.
    发明申请
    Pharmaceutical composition for immunization against AIDS 审中-公开
    用于免疫艾滋病的药物组合物

    公开(公告)号：US20050118188A1

    公开(公告)日：2005-06-02

    申请号：US10957010

    申请日：2004-10-01

    申请人： Francois Dalenccon ,  Jean Haensler

    发明人： Francois Dalenccon ,  Jean Haensler

    IPC分类号： A61K39/21 ,  A61K39/39 ,  A61P31/00 ,  A61K39/02

    CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/545 ,  A61K2039/55511 ,  A61K2039/55561 ,  A61K2039/57 ,  C12N2740/16134

    摘要： The invention relates to the field of pharmaceutical compositions for use in immunization against HIV-related infections, and concerns a pharmaceutical composition comprising at least an HIV antigen and DCchol. Such a composition has proved to be particularly interesting for inducing through the mucus system IgG and IgA specific to the administered antigen. The inventive pharmaceutical composition, in a particularly advantageous manner, can be in the form of a liposome suspension or emulsion.

    摘要翻译： 本发明涉及用于免疫HIV相关感染的药物组合物领域，涉及包含至少一种HIV抗原和DCchol的药物组合物。 已经证明，通过对施用的抗原特异性的粘液系统IgG和IgA诱导这种组合是特别有趣的。 本发明的药物组合物以特别有利的方式可以是脂质体悬浮液或乳液的形式。